Advancing foundational research from UCLA and Migal – Galilee Research Institute, ImmPact is working on T-cell therapies for liquid and solid cancers.
ImmPact Bio, a US-based developer of cancer treatments based on research at University of California, Los Angeles (UCLA) and Migal – Galilee Research Institute, picked up $111m in a series B round yesterday. VenBio Partners, Foresite Capital and Decheng Capital led the round, in which pharmaceutical firms Bukwang Pharmaceutical and Novartis – the latter through…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
